New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export ABBV’s income statement to Excel — free account
AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
288.54
5.03
+1.77%
Follow ABBV
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Free cash flow of $7.3B covered $3.1B of dividends and buybacks. Cash rose by $4.2B. What is a cash flow statement?
- Free cash flow
- $7.3B 96.0% of operating cash flow
- Returned to shareholders
- $3.1B 42.1% of free cash flow
- Debt, net
- $10.0B borrowed
- Change in cash
- +$4.2B over the period
| Operating cash flow | 7.6 |
|---|---|
| Capital expenditures | −0.3 |
| Free cash flow | 7.3 |
| Acquisitions, net | −10.9 |
| Dividends | −3.1 |
| Debt raised, net | +10.0 |
| Other | +0.9 |
| Change in cash | 4.2 |
Free cash flow
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Operating cash flow | $5.2B | $3.8B | $3.4B | $7.6B |
| Capex | −$329M | −$265M | −$322M | −$301M |
| Free cash flow | $4.9B | $3.6B | $3.1B | $7.3B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Net Income |
4,220.00 | 3,616.00 | 697.00 | 1,815.00 |
+8 more quarters Free account |
Depreciation & Amortization |
1,861.00 | 1,883.00 | 1,936.00 | 1,987.00 | |
Non Cash Items (Other) |
(157.00) | 654.00 | 3,140.00 | 1,898.00 | |
Accounts Receivable Change |
312.00 | (1,369.00) | 87.00 | 162.00 | |
Change in inventories |
(148.00) | (143.00) | (184.00) | (25.00) | |
Accounts Payable Change |
983.00 | 1,202.00 | (1,594.00) | (598.00) | |
Income tax paid |
301.00 | (2,223.00) | (81.00) | 646.00 | |
Change in other assets and liabilities |
234.00 | (184.00) | (172.00) | (667.00) | |
Operating Cash Flow |
7,606.00 | 3,436.00 | 3,829.00 | 5,218.00 | |
Capital expenditures |
(301.00) | (322.00) | (265.00) | (329.00) | |
Net Aquisitions |
(10,860.00) | (824.00) | (266.00) | (1,161.00) | |
Long-Term Investments Change (Net) |
— | — | — | 28.00 | |
Other investing activities |
946.00 | (51.00) | (43.00) | (14.00) | |
Investing cash flow |
(10,215.00) | (1,197.00) | (574.00) | (1,463.00) | |
Repayment/Issuance of Debt (Net) |
9,983.00 | (2,000.00) | 5,492.00 | (1,299.00) | |
Equity Repurchase (Common, Net) |
(5.00) | (9.00) | (1,489.00) | 169.00 | |
Dividends Paid (Total) |
(3,071.00) | (3,070.00) | (3,086.00) | (2,911.00) | |
Other financial activities |
(87.00) | 25.00 | 2.00 | (125.00) | |
Financing cash flow |
6,820.00 | (5,054.00) | 919.00 | (4,166.00) | |
Exchange Rate Adjustment |
(6.00) | (7.00) | (12.00) | 11.00 | |
Change in Cash |
4,205.00 | (2,822.00) | 4,162.00 | (400.00) | |
Beginning Cash |
0.00 | 0.00 | 5,229.00 | 0.00 | |
Ending Cash |
4,205.00 | (2,822.00) | 9,391.00 | (400.00) | |
Stock Based Compensation |
160.00 | 166.00 | 444.00 | 157.00 | |
Dividends Paid (Common) |
(3,071.00) | (3,070.00) | (3,086.00) | (2,911.00) | |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
1,682.00 | (2,717.00) | (1,944.00) | (482.00) | |
Investments Change (Net) |
— | — | — | 28.00 | |
Issuance/Purchase of Shares |
(5.00) | (9.00) | (1,489.00) | 169.00 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026